Clinical Trials

Great Falls Clinic Open Research Studies

Learn more about Great Falls Clinic’s Clinical Research Department.

20170625 (Vesalius): Phase III

Treating: Coronary Heart Disease
Investigator(s): PI: Dr. Libby Lake, Sub-I: Ellen Sparks, PA-C

Indication: Reduce the risk of Coronary Heart Disease (CHD) death, myocardial infarction (MI), stroke, and ischemia-driven arterial revascularization in adults at high risk of cardiovascular events without prior MI or stroke
Status: Open/Currently Enrolling
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Rike Without Prior Myocardial Infarction or Stroke

ATB200-02: Phase I/II

Treating: Pompe Disease
Investigator(s): PI: Dr. Karl Guter, Sub-I: Dr. Thomas Warr

Indication: Pompe Disease
Status: Open/Currently Not Enrolling
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-administered With Oral AT2221 in Adult Subjects With Pompe Disease

CAIN457H2315: Phase III

Treating: Axial Spondyloarthritis
Investigator(s): PI: Dr. Libby Lake, Sub-I: Dr. Karl Guter

Indication: Active non-radiographic Axial Spondyloarthritis
Status: Open and Currently Not Enrolling
A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis

CAIN457K2340: Phase III

Treating: Axial Spondyloarthritis
Investigator(s): PI: Dr. Karl Guter, Sub-I: Dr. Libby Lake

Indication: Active radiographic Axial Spondyloarthritis
Status: Open and Currently Not Enrolling
A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis

D169CC00001 (Deliver-HF): Phase III

Treating: Heart Failure
Investigator(s): PI: Dr. Jorge Castriz, Sub-I: Ellen Sparks, PA-C

Status: Open/Currently enrolling
An international, double-blind, randomized, placebo-controlled phase III study to evaluate the effect of Dapagliflozin on reducing CV death or worsening heart failure in patient with heart failure with preserved ejection fraction (HFpEF)

EFC14828 (Amplitude-O): Phase III

Treating: Diabetes
Investigator(s): PI: Dr. Thomas Warr, Sub-I: Dr. Libby Lake

Status: Open/Currently Not Enrolling
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of Efpeglenatide on cardiovascular outcomes in type 2 diabetes patients at high cardiovascular risk

Meet Our Providers

Andrea Withey, RDN

Diabetes / Nutrition Services

Benjamin Keggi, DO

Family Practice

Antonio Santin, MD, FACS

Otolaryngology

Plastic Surgery

Russell Herring, DNP

Family Practice